Shares of ViroPharma ( VPHM) were among the best-performing health-related stocks Monday, rising 11% after the pharmaceutical company posted third-quarter earnings and sales that trounced Wall Street expectations.

The company earned $18.7 million, or 31 cents a share, on sales of $35.8 million. Analysts polled by Thomson First Call expected earnings of 21 cents a share and sales of $29.5 million. In the year-ago quarter, the company had a loss of $3.3 million, or 13 cents a share, on sales of $398,000. The company attributed the improved results to Vancocin, a colitis treatment. Vancocin had third-quarter sales of $35.7 million, with prescriptions up 36% from the year-earlier period.

ViroPharma increased its full-year Vancocin sales projection to $120 million to $123 million from its August forecast of $100 million to $105 million. Analysts expect sales of $119.8 million. Shares recently were trading up $2.27 to $23.26.

Dendreon ( DNDN) climbed 8% after the company's Provenge prostate cancer treatment received fast-track status from the Food and Drug Administration. The designation, given for drugs that address an unmet medical need and treat life-threatening conditions, allows Dendreon to submit its biologics license application for Provenge on a rolling basis. Shares rose 45 cents to $6.03.

Shares of China Medical Technologies ( CMED) rose 10% after the medical device company posted large year-over-year gains in second-quarter earnings and sales. China Medical earned $5.3 million, or 22 cents per American depositary share, on sales of $10.9 million. Earnings during the recent period jumped 61.3% while sales increased by 81.6%. The lone analyst forecast called for earnings of 19 cents a share and sales of $10.4 million. "The strong growth of our sales of the ECLIA system since its introduction in September 2004 contributed to the substantial year-over-year growth in both our net revenues and net income for the quarter," the company said.

China Medical sees full-year earnings of $21.6 million to $23.5 million, and sales of $44.5 million to $49.4 million. One analyst polled by First Call projects earnings of $22.8 million on sales of $46.8 million. The company's shares gained $2.19 to $24.45.

Misonix ( MSON) slumped 24% after the ultrasonic medical systems maker reported that it swung to a first-quarter loss. The company reported a loss of $1.3 million, or 19 cents a share, reversing a year-earlier profit of $416,000, or 6 cents a share. Sales dropped to $9.1 million from $10.5 million a year earlier. Medical device sales fell 16% to $5 million, while lab and scientific product sales fell 10% to $4.1 million. Shares were trading down $1.48 to $4.79.

Other health care volume movers included Pfizer ( PFE), down 4 cents to $22.22; Guidant ( GDT), down $1.83 to $57.09; Johnson & Johnson ( JNJ), up 2 cents to $60.90; Amgen ( AMGN), up 83 cents to $80.02; Imclone Systems ( IMCL), up $1.54 to $32.39; Merck ( MRK), up 12 cents to $29.34; UnitedHealth Group ( UNH), up 51 cents to $58.53; Novavax ( NVAX), up 7 cents to $3.99; and Schering-Plough ( SGP), down 17 cents to $19.86.

More from Stocks

Musk's The Boring Company Just Got a Bit Less Boring

Musk's The Boring Company Just Got a Bit Less Boring

Tyson Foods CEO: We Aren't Done Making Deals

Tyson Foods CEO: We Aren't Done Making Deals

Dow Drops Over 100 Points on Trade War Worries

Dow Drops Over 100 Points on Trade War Worries

Warren Buffett at Age 87 Still Does One Amazing Thing That Drives Success

Warren Buffett at Age 87 Still Does One Amazing Thing That Drives Success

Amazon, Nvidia, Micron and 10 Other Stocks to Own in June

Amazon, Nvidia, Micron and 10 Other Stocks to Own in June